Impact of High-Dose Chemotherapy on the Ability to Deliver Subsequent Local-Regional Radiotherapy for Breast Cancer: Analysis of Cancer and Leukemia Group B Protocol 9082

International Journal of Radiation Oncology Biology Physics

Volumn 76, Issue 5, 2010, Pages 1305-1313

  Marks, Lawrence B ^a,f   Cirrincione, Constance ^b   Fitzgerald, Thomas J ^c,d   Laurie, Frances ^d   Glicksman, Arvin S ^d,e   Vredenburgh, James ^f   Prosnitz, Leonard R ^f   Shpall, Elizabeth J ^g   Crump, Michael ^h   Richardson, Paul G ⁱ   Schuster, Michael W ^j   Ma, Jinli ^f,k   Peterson, Bercedis L ^b   Norton, Larry ^l   Seagren, Steven ^m   Henderson, I Craig ⁿ   Hurd, David D ^o   Peters, William P ^p  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d Quality Assurance Review Center   (United States)

^e Rhode Island Cancer Council   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h PRINCESS MARGARET HOSPITAL   (Canada)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^k FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o WAKE FOREST SCHOOL OF MEDICINE   (United States)

^p WAYNE STATE UNIVERSITY   (United States)

more..

Author keywords

Breast cancer; High dose chemotherapy; Radiotherapy; Toxicity

Indexed keywords

AFRICAN AMERICAN; AXILLARY NODES; BREAST CANCER; CIS-PLATIN; EARLY TERMINATION; ESTROGEN RECEPTOR; HIGH DOSE; HIGH-DOSE CHEMOTHERAPIES; HIGH-DOSE CHEMOTHERAPY; HIGH-DOSE TREATMENT; MULTI VARIATE ANALYSIS; ODDS RATIOS;

CHEMOTHERAPY; DECISION MAKING; MULTIVARIANT ANALYSIS; PLATINUM COMPOUNDS; RADIOTHERAPY; TOXICITY;

BREAKWATERS;

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; TAMOXIFEN;

ADULT; AFRICAN AMERICAN; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; ETHNICITY; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CANADA; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; RADIOTHERAPY DOSAGE;

EID: 77949556764     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.04.013     Document Type: Article

References (58)

1. Jones S.E., Moon T.E., Bonadonna G., et al. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history database. Am J Clin Oncol 10 (1987) 387-395
2. Hellman S., and Harris J.R. Natural history of breast cancer. In: Harris J.R., Lippman M.E., and Morrow M. (Eds). Diseases of the breast. 2nd ed. (2000), Lippincott Williams & Wilkins, Philadelphia 407-424
3. Hoehne F., Chen S., Mabry H., et al. An update on prognosis in breast cancer patients with extensive axillary disease. Breast J 14 (2008) 76-80
4. Rack B., Janni W., Gerber B., et al. Patients with recurrent breast cancer: Does the primary axillary lymph node status predict more aggressive tumor progression?. Breast Cancer Res Treat 82 (2003) 83-92
5. Montero A.J., Rouzier R., Lluch A., et al. The natural history of breast carcinoma in patients with ≥10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: A multi-institutional retrospective study. Cancer 104 (2005) 229-235
6. Geara F.B., Nasr E., Tucker S.L., et al. Breast cancer patients with 10 or more involved axillary lymph nodes treated by multimodality therapy: Influence of clinical presentation on outcome. Int J Radiat Oncol Biol Phys 68 (2007) 364-369
7. Frei E., and Canellos G.P. Dose: A critical factor in cancer chemotherapy. Am J Med 69 (1980) 585-594
8. Hryniuk W., and Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2 (1984) 1281-1288
9. Hryniuk W., and Levine M.N. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4 (1986) 1162-1170
10. Eddy D.M. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. J Clin Oncol 10 (1992) 657-670
11. Fisher B., Anderson S., Wickerham D.L., et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15 (1997) 1858-1869
12. Peters W.P., Ross M., Vredenburgh J.J., et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11 (1993) 1132-1143
13. Peters W, Rosner GL, Vredenburgh JJ, et al. Updated results of a prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): CALGB 9082/SWOG 9114/NCIC (Abstr.). Presented at the 37th Annual Meeting of the America Society of Clinical Oncology, May 12-15, 2001, San Francisco, CA.
14. Peters W.P., Rosner G.L., Vredenburgh J.J., et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: A report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 23 (2005) 2191-2200
15. Ragaz J., Jackson S.M., Le N., et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 337 (1997) 956-962
16. Blomqvist C., Tiusanen K., Elomaa I., et al. The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial. Br J Cancer 66 (1992) 1171-1176
17. Rutqvist L.E., Cedermark B., Glas U., et al. Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: A summary of three randomized trials. Int J Radiat Oncol Biol Phys 16 (1989) 629-639
18. Overgaard M., Hansen P.S., Overgaard J., et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 337 (1997) 949-955
19. Overgaard M., Jensen M.B., Overgaard J., et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 353 (1999) 1641-1648
20. Martinez A., Ahmann D., and O'Fallow J. An interim analysis of the randomized surgical adjuvant trial for patients with unfavorable breast cancer. Int J Radiat Oncol Biol Phys 10 Suppl. 2 (1984) 106
21. McArdle C.S., Crawford D., Dykes E.H., et al. Adjuvant radiotherapy and chemotherapy in breast cancer. Br J Surg 73 (1986) 264-266
22. Moss W.T., Brand W.N., and Battifora H. Radiation oncology. Rationale, technique, results (1979), C.V. Mosby, St. Louis
23. Griem K.L., Henderson I.C., Gelman R., et al. The 5-year results of a randomized trial of adjuvant radiation therapy after chemotherapy in breast cancer patients treated with mastectomy. J Clin Oncol 5 (1987) 1546-1555
24. Overgaard M., Nielsen H.M., and Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 82 (2007) 247-253
25. Nielsen H.M., Overgaard M., Grau C., et al. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: Long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol 24 (2006) 2268-2275
26. Marks L.B., Hebert M.E., Bentel G., et al. To treat or not to treat the internal mammary nodes: A possible compromise. Int J Radiat Oncol Biol Phys 29 (1994) 903-909
27. Rodenhuis S., Richel D.J., van der Wall E., et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 352 (1998) 515-521
28. Winer E.P. Quality-of-life research in patients with breast cancer. Cancer 74 (1994) 410-415
29. Damon L.E., Hu W.W., Stockerl-Goldstein K.E., et al. High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: Experience in California. Biol Blood Marrow Transplant 6 (2000) 496-505
30. de Graaf H., Willemse P.H., de Vries E.G., et al. Intensive chemotherapy with autologous bone marrow transfusion as primary treatment in women with breast cancer and more than five involved axillary lymph nodes. Eur J Cancer 30A (1994) 150-153
31. Roche H., Viens P., Biron P., et al. High-dose chemotherapy for breast cancer: The French PEGASE experience. Cancer Control 10 (2003) 42-47
32. Farquhar C., Basser R., Marjoribanks J., et al. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. Cochrane Database Syst Rev (2003) CD003139
33. Farquhar C., Basser R., Hetrick S., et al. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. Cochrane Database Syst Rev (2003) CD003142
34. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med 333 (1995) 1444-1455
35. Fisher B., Anderson S., Redmond C.K., et al. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 333 (1995) 1456-1461
36. Fisher B., Anderson S., Bryant J., et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347 (2002) 1233-1241
37. Fisher B., Jeong J.H., Anderson S., et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347 (2002) 567-575
38. Citron M.L., Berry D.A., Cirrincione C., et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21 (2003) 1431-1439
39. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28. 2005;23:3686-3696.
40. Overgaard M., Christensen J.J., Johansen H., et al. Evaluation of radiotherapy in high-risk breast cancer patients: Report from the Danish Breast Cancer Cooperative Group (DBCG 82). Trial. Int J Radiat Oncol Biol Phys 19 (1990) 1121-1124
41. Nielsen H.M., Overgaard J., Grau C., et al. Audit of the radiotherapy in the DBCG 82 b&c trials-A validation study of the 1,538 patients randomised to postmastectomy radiotherapy. Radiother Oncol 76 (2005) 285-292
42. Bentel G., Marks L.B., Hardenbergh P., et al. Variability of the location of internal mammary vessels and glandular breast tissue in breast cancer patients undergoing routine CT-based treatment planning. Int J Radiat Oncol Biol Phys 44 (1999) 1017-1025
43. Marks L.B., Halperin E.C., Prosnitz L.R., et al. Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes. Cancer and Leukemia Group B. Int J Radiat Oncol Biol Phys 23 (1992) 1021-1026
44. Moreno M., Azinovic I., Lopez-Picazo J.M., et al. Radiation therapy after high-dose chemotherapy with peripheral blood stem cell support for high-risk breast cancer. Am J Clin Oncol 25 (2002) 347-353
45. Buchholz T.A., Tucker S.L., Moore R.A., et al. Importance of radiation therapy for breast cancer patients treated with high-dose chemotherapy and stem cell transplant. Int J Radiant Oncol Biol Phys 46 (2000) 337-343
46. Moore H.C., Mick R., Solin L.J., et al. Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: impact on the delivery of local-regional radiation therapy. Ann Oncol 10 (1999) 929-936
47. Optenberg S.A., Thompson I.M., Friedrichs P., et al. Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. JAMA 274 (1995) 1599-1605
48. Demark-Wahnefried W., Schildkraut J.M., Iselin C.E., et al. Treatment options, selection, and satisfaction among African American and white men with prostate carcinoma in North Carolina. Cancer 83 (1998) 320-330
49. Banerjee M., George J., Yee C., et al. Disentangling the effects of race on breast cancer treatment. Cancer 110 (2007) 2169-2177
50. Shen Y., Dong W., Esteva F.J., et al. Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center?. Breast Cancer Res Treat 102 (2007) 347-356
51. Bach P.B., Cramer L.D., Warren J.L., et al. Racial differences in the treatment of early-stage lung cancer. N Engl J Med 341 (1999) 1198-1205
52. Canto J.G., Allison J.J., Kiefe C.I., et al. Relation of race and sex to the use of reperfusion therapy in Medicare beneficiaries with acute myocardial infarction. N Engl J Med 342 (2000) 1094-1100
53. Peterson E.D., Shaw L.K., DeLong E.R., et al. Racial variation in the use of coronary-revascularization procedures. Are the differences real? Do they matter?. N Engl J Med 336 (1997) 480-486
54. Bickell N.A. Race, ethnicity, and disparities in breast cancer: Victories and challenges. Womens Health Issues 12 (2002) 238-251
55. Hahn K.M., Bondy M.L., Selvan M., et al. Factors associated with advanced disease stage at diagnosis in a population-based study of patients with newly diagnosed breast cancer. Am J Epidemiol 166 (2007) 1035-1044
56. Gorey K.M., Luginaah I.N., Schwartz K.L., et al. Increased racial differences on breast cancer care and survival in America: Historical evidence consistent with a health insurance hypothesis, 1975-2001. Breast Cancer Res Treat 113 (2009) 595-600
57. Ayanian J.Z., Cleary P.D., Weissman J.S., et al. The effect of patients' preferences on racial differences in access to renal transplantation. N Engl J Med 341 (1999) 1661-1669
58. Griggs J.J., Culakova E., Sorbero M.E., et al. Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol 25 (2007) 2522-2527